REFERENCES
- PaleIla FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
- Trotta MP, Ammassari A, Melzi S, et al. Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir. Immune Defic Syndr. 2002;31 (suppl 3):S128–131.
- Knobel H, Guelar A. Strategies to optimize adherence to antiretroviral treatment. Interventions in the therapeutic regi-men. Enferm Infecc Microbiol Clin. 2004;22(2):106–112.
- Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1875–1883.
- Raffi F, Bonnet B, Ferre V, et al. Substitution of a nonnucleoside reverse transcriptase inhibitor for a pro-tease inhibitor in the treatment of patients with undetect-able plasma human inmunodeficiency virus type 1 RNA. Clin Infect Dis. 2000;31:1274–1278.
- Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus con-tinued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS. 2001;15:1517–1526.
- Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treat-ment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr. 2001;27: 229–236.
- Negredo E, Cruz L, Paredes R, et al. Virological, inmunological and clinical impact of switching from pro-tease inhibitors to nevirapine or to efavirenz in patients with human inmunodeficiency virus and long-lasting viral sup-pression. Clin Infect Dis. 2002;34:504–510.
- Ammassari A, Murri R, Pezotti P, Trotta MP, Ravasio L, De Longis P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antirretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28:445–449.
- Duran S, Saves M, Spire B, et al. Failure to mantain long-term adherence to highly active antiretroviral therapy: the role of lypodistrophy. mns 2001;15:2441–2444.
- Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002;29:52–S10.
- AIDS Clinical Trials Group. Table for grading severity of adult adverse experiencies. August 1992. Available at: http://aactg.s-3.com/members/adulttox.htm. Accessed September 2004.
- Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS. 2002;16(4):605–613.
- Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.
- Gil P, Gorgolas M, Estrada V, et al. Long-term efficacy and safety of protease inhibitor switching to nevirapine HIV-infected patients with undetectable virus load. Clin Infect Dis. 2004;39:1024–1029.
- Maggiolo F, Ripamonti D, Ravasio L, et al. Outcome of 2 simplification strategies for the treatment of human immu-nodeficiency virus type 1 infection. Clin Infect Dis. 2003;37: 41–49.
- Negredo E, Cruz L, Paredes R, et al. Reversal of athero-genic lipoprotein profile in HIV-infected patients with lipod-ystrophy alter replacing protease inhibitors by nevirapine. AIDS. 2002;16:1383–1389.
- Martinez E, Conget I, Lozano L, Casamitjana R, Gate JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13: 805–810.
- Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human inmunodeficiency virus infection. N Engl J Med. 2003;349:1036–1046.